Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
Authors
Keywords
-
Journal
RMD Open
Volume 8, Issue 2, Pages e002280
Publisher
BMJ
Online
2022-07-28
DOI
10.1136/rmdopen-2022-002280
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
- (2021) Atul Deodhar et al. ANNALS OF THE RHEUMATIC DISEASES
- Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
- (2021) Iain B. McInnes et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold?
- (2021) Nurullah Akkoc et al. Current Rheumatology Reports
- POS0918 EVALUATION OF SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING IXEKIZUMAB THERAPY OVER 2 YEARS
- (2021) D. Van der Heijde et al. ANNALS OF THE RHEUMATIC DISEASES
- Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
- (2021) Ulf Lindström et al. ANNALS OF THE RHEUMATIC DISEASES
- Upadacitinib in Active Ankylosing Spondylitis: 1‐Year Results From the Double‐Blind, Placebo‐Controlled SELECT‐AXIS 1 Study and Open‐Label Extension
- (2021) Atul Deodhar et al. Arthritis & Rheumatology
- Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years
- (2021) Désirée van der Heijde et al. JOURNAL OF RHEUMATOLOGY
- Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
- (2020) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of venous thromboembolism in ankylosing spondylitis: a general population-based study
- (2019) Juan Antonio Aviña-Zubieta et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial
- (2019) Désirée van der Heijde et al. LANCET
- Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states
- (2018) Pedro M Machado et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
- (2018) Josef S. Smolen et al. JOURNAL OF RHEUMATOLOGY
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Désirée van der Heijde et al. LANCET
- Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
- (2018) Jürgen Braun et al. RHEUMATOLOGY
- Axial spondyloarthritis
- (2017) Joachim Sieper et al. LANCET
- Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
- (2016) Jürgen Braun et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination
- (2016) Huifeng Yun et al. Arthritis & Rheumatology
- Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
- (2015) J. Sieper et al. Arthritis & Rheumatology
- Brief Report: Calculating the Ankylosing Spondylitis Disease Activity Score If the Conventional C-Reactive Protein Level Is Below the Limit of Detection or If High-Sensitivity C-Reactive Protein Is Used: An Analysis in the DESIR Cohort
- (2015) Pedro Machado et al. Arthritis & Rheumatology
- Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis
- (2013) Carmen Stolwijk et al. ANNALS OF THE RHEUMATIC DISEASES
- Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis
- (2013) D van der Heijde et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
- (2012) Joachim Sieper et al. ANNALS OF THE RHEUMATIC DISEASES
- Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
- (2011) Jürgen Braun et al. ANNALS OF THE RHEUMATIC DISEASES
- The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis
- (2009) J Sieper et al. ANNALS OF THE RHEUMATIC DISEASES
- Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years
- (2009) Désirée van der Heijde et al. ARTHRITIS RESEARCH & THERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search